A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA.

Zilebesiran, an investigational RNA interference therapeutic targeting angiotensinogen, represents a paradigm-shifting approach to managing resistant hypertension in patients with CKD.